Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216224%3A14110%2F15%3A00084399" target="_blank" >RIV/00216224:14110/15:00084399 - isvavai.cz</a>
Alternative codes found
RIV/61989592:15110/15:33155483 RIV/65269705:_____/15:00063313
Result on the web
<a href="http://dx.doi.org/10.1186/s12876-015-0266-6" target="_blank" >http://dx.doi.org/10.1186/s12876-015-0266-6</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1186/s12876-015-0266-6" target="_blank" >10.1186/s12876-015-0266-6</a>

Result language
angličtina
Original language name
Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view
Original language description
Background: The aim of the present retrospective study was to analyze clinical outcome and risk factors associated with treatment outcomes according to KRAS status in patient with metastatic colorectal cancer (mCRC) treated with bevacizumab (bev) plus chemotherapy in the first-line setting. Methods: We performed observational study on 1622 patients with mCRC treated with bev plus oxaliplatin- or irinotecan-based chemotherapy, and correlated treatment outcomes with KRAS mutation status. The primary endpoint was progression-free survival (PFS) and additionally overall survival (OS). Adverse events of bevacizumab and risk factors including location of metastases were evaluated. Results: Mutation in KRAS was present in 40.6% of mCRC cases. The median PFS in patients with wild-type KRAS (wtKRAS) vs mutant KRAS was 11.5 vs 11.4 months, respectively. The median OS was 30.7 vs 28.4 months (p = 0.312). Patients with KRAS mutation had lung metastases more frequently than wtKRAS individuals (32.0
Czech name
—
Czech description
—

Type
J<sub>x</sub> - Unclassified - Peer-reviewed scientific article (Jimp, Jsc and Jost)
CEP classification
FE - Other fields of internal medicine
OECD FORD branch
—

Project
<a href="/en/project/LM2010004" target="_blank" >LM2010004: BBMRI_CZ in the building of the Czech part of a large distributed research infrastructure of pan-European importance: the creation and operation of the network of banks of biological material for biomedical research</a><br>
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Publication year
2015
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)